Search

Displaying results 3101 - 3110 of 9670 in total
  1. Drug

    Odevixibat

    go.drugbank.com/drugs/DB16261
    ApprovedInvestigational

    [L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid]. … [A236808] Odevixibat was granted FDA and Health Canada approval on 20 July 2021 and 13 November 2023 respectively.[L34793,L49535]

  2. Drug

    Human papillomavirus type 33 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10311
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 33.

    Mixtures: GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO, GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO
  3. Drug

    Human papillomavirus type 45 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10312
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 45.

    Mixtures: GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO, GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO
  4. Drug

    Human papillomavirus type 58 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10314
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 58.

    Mixtures: GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO, GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO
  5. Drug

    Indium In-111 chloride

    go.drugbank.com/drugs/DB09490
    Approved

    It is supplied as a sterile, pyrogen-free solution of Indium ("'In) Chloride in O.04M HCI.

  6. Drug

    Berahyaluronidase alfa

    go.drugbank.com/drugs/DB22790
    ApprovedInvestigational

    It is used in a fixed-dose combination with [pembrolizumab] for subcutaneous injection. … This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications

  7. Drug

    Crotalus atrox antivenin

    go.drugbank.com/drugs/DB13892
    Approved

    It is intravenously (IV) administered to prevent/limit systemic toxicity [FDA label]. … Crotalus atrox antivenin is derived and purified immunoglobulin fragments obtained from other domestic animals such as sheep previously immunized with Crotalus atrox (Western Diamondback rattlesnake).

  8. Drug

    Carbetocin

    go.drugbank.com/drugs/DB01282
    ApprovedInvestigational

    It is an analogue of oxytocin, and its action is similar to that of oxytocin -- it causes contraction of the uterus.

  9. Drug

    Benzimate

    go.drugbank.com/drugs/DB05170
    Experimental

    It is currently under investigation by AmpliMed and is in phase I of clinical trial. … Benzimate is the lead compound selected from a series of compounds known as benzimidazoles.

  10. Drug

    Meticrane

    go.drugbank.com/drugs/DB13284
    Approved

    It has been marketed in Japan under the trade name Arresten and is used to lower blood pressure [L5647].